Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT04516811
PHASE3

Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19

Sponsor: South African National Blood Service

View on ClinicalTrials.gov

Summary

A prospective, randomized, placebo-controlled, double-blinded, phase III clinical trial of the therapeutic use of convalescent plasma in the treatment of patients with moderate to severe COVID-19

Official title: A Prospective, Randomized, Placebo-controlled, Double-blinded, Phase III Clinical Trial of the Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

102

Start Date

2020-09-21

Completion Date

2022-07-31

Last Updated

2026-05-08

Healthy Volunteers

No

Interventions

BIOLOGICAL

COVID-19 convalescent plasma (CCP) plus standard of care (SOC)

A single unit of approximately 200-250 mL of CCP that contains anti-SARS-CoV-2 collected by plasmapheresis from a volunteer who recovered from COVID19 with SOC as determined by local practice and guidelines.

BIOLOGICAL

Standard of care (SOC) plus placebo

A single unit of 200 mL normal saline with SOC as determined by local practice and guidelines

Locations (2)

Universitas Hospital

Bloemfontein, Free State, South Africa

Mitchells Plain Hospital

Cape Town, Western Cape, South Africa